Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

This study is testing a combination of two drugs — eflornithine (DFMO) and AMXT 1501 — in children, adolescents, and young adults with neuroblastoma, certain brain tumors, or sarcomas that have returned or stopped responding to treatment. The drugs target a cellular pathway that helps tumors grow. **You may be eligible if...** - You are 21 years old or younger at the time of diagnosis - You have a confirmed diagnosis of neuroblastoma, a specific CNS tumor, or sarcoma that has relapsed or is refractory - You are in reasonable health with adequate organ function **You may NOT be eligible if...** - You have had too many prior lines of therapy without adequate recovery - Your disease has spread in ways that make safe participation difficult Talk to your doctor to see if this trial is right for you.